DIM
CRVS icon

DC Investments Management’s Corvus Pharmaceuticals CRVS Stock Holding History

DC Investments Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50,709
Closed -$245K – 63
2021
Q3 		$245K Buy
+50,709
New +$150K 0.46% 45

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

DC Investments Management's CRVS Position: Q4 2021 in Review

DC Investments Management sold out of Corvus Pharmaceuticals (CRVS) in Q4 2021, closing a stake of 50,709 shares — an estimated $245K sold.

DC Investments Management first reported a position in CRVS in Q3 2021 and held it in 1 quarter. The position peaked at $245K in Q3 2021. 62 funds tracked by Wall St. Rank hold CRVS as of Q4 2021.

  • DC Investments Management reported no remaining Corvus Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • DC Investments Management sold 50,709 Corvus Pharmaceuticals shares in Q4 2021, an estimated $245K.
  • DC Investments Management first reported a position in Corvus Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • DC Investments Management's Corvus Pharmaceuticals position peaked at $245K in Q3 2021.
  • 62 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2021.

Based on DC Investments Management's 13F filing for Q4 2021, filed 11 Feb 2022.